A detailed history of Aspiriant, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Aspiriant, LLC holds 8,092 shares of BMY stock, worth $471,197. This represents 0.02% of its overall portfolio holdings.

Number of Shares
8,092
Previous 6,789 19.19%
Holding current value
$471,197
Previous $281,000 48.75%
% of portfolio
0.02%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$39.66 - $51.75 $51,676 - $67,430
1,303 Added 19.19%
8,092 $418,000
Q2 2024

Jul 15, 2024

SELL
$40.25 - $52.99 $93,742 - $123,413
-2,329 Reduced 25.54%
6,789 $281,000
Q1 2024

Apr 15, 2024

BUY
$47.98 - $54.4 $33,681 - $38,188
702 Added 8.34%
9,118 $494,000
Q4 2023

Jan 26, 2024

BUY
$48.48 - $57.85 $41,159 - $49,114
849 Added 11.22%
8,416 $431,000
Q3 2023

Oct 17, 2023

SELL
$57.89 - $64.73 $350,466 - $391,875
-6,054 Reduced 44.45%
7,567 $439,000
Q2 2023

Jul 19, 2023

SELL
$63.71 - $70.74 $46,890 - $52,064
-736 Reduced 5.13%
13,621 $871,000
Q1 2023

Apr 27, 2023

SELL
$65.71 - $74.53 $3,285 - $3,726
-50 Reduced 0.35%
14,357 $995,000
Q4 2022

Jan 23, 2023

BUY
$68.48 - $81.09 $95,050 - $112,552
1,388 Added 10.66%
14,407 $0
Q3 2022

Oct 28, 2022

BUY
$0.13 - $76.84 $14 - $8,529
111 Added 0.86%
13,019 $925,000
Q2 2022

Jul 25, 2022

BUY
$72.62 - $79.98 $196,582 - $216,505
2,707 Added 26.54%
12,908 $995,000
Q1 2022

May 06, 2022

SELL
$61.48 - $73.72 $115,643 - $138,667
-1,881 Reduced 15.57%
10,201 $745,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $237,259 - $276,588
4,424 Added 57.77%
12,082 $753,000
Q3 2021

Oct 27, 2021

SELL
$59.17 - $69.31 $7,396 - $8,663
-125 Reduced 1.61%
7,658 $453,000
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $4,271 - $4,651
69 Added 0.89%
7,783 $519,000
Q1 2021

May 11, 2021

BUY
$59.34 - $66.74 $52,812 - $59,398
890 Added 13.04%
7,714 $487,000
Q4 2020

Feb 01, 2021

BUY
$57.74 - $65.43 $21,479 - $24,339
372 Added 5.77%
6,824 $422,000
Q3 2020

Oct 29, 2020

BUY
$57.43 - $63.64 $1,665 - $1,845
29 Added 0.45%
6,452 $390,000
Q2 2020

Aug 06, 2020

SELL
$54.82 - $64.09 $21,599 - $25,251
-394 Reduced 5.78%
6,423 $377,000
Q1 2020

May 05, 2020

SELL
$46.4 - $67.43 $464 - $674
-10 Reduced 0.15%
6,817 $381,000
Q4 2019

Jan 27, 2020

BUY
$49.21 - $64.19 $35,628 - $46,473
724 Added 11.86%
6,827 $440,000
Q3 2019

Nov 04, 2019

SELL
$42.77 - $50.71 $13,985 - $16,582
-327 Reduced 5.09%
6,103 $312,000
Q2 2019

Aug 06, 2019

SELL
$44.62 - $49.34 $71,704 - $79,289
-1,607 Reduced 20.0%
6,430 $291,000
Q1 2019

May 03, 2019

SELL
$45.12 - $53.8 $24,409 - $29,105
-541 Reduced 6.31%
8,037 $382,000
Q4 2018

Feb 04, 2019

SELL
$48.76 - $63.23 $57,341 - $74,358
-1,176 Reduced 12.06%
8,578 $447,000
Q3 2018

Oct 26, 2018

SELL
$55.19 - $62.25 $259,061 - $292,201
-4,694 Reduced 32.49%
9,754 $605,000
Q2 2018

Aug 07, 2018

SELL
$50.53 - $62.98 $345,877 - $431,098
-6,845 Reduced 32.15%
14,448 $800,000
Q1 2018

May 04, 2018

BUY
$59.92 - $68.98 $1.28 Million - $1.47 Million
21,293 New
21,293 $1.35 Million
Q4 2017

Jan 31, 2018

SELL
$59.94 - $65.35 $919,479 - $1 Million
-15,340 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $847,228 - $977,771
15,340
15,340 $978,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Aspiriant, LLC Portfolio

Follow Aspiriant, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aspiriant, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aspiriant, LLC with notifications on news.